A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

Clinical trial NCT03789617 · UNKNOWN

Trial details

NCT number: NCT03789617
Sponsor: Eutilex
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

EBV Associated Extranodal NK/T-cell Lymphoma EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma

Start date: 2018-12-14
Primary completion: 2022-09-01
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.